Home » Stocks » Geron

Geron Corporation (GERN)

Stock Price: $1.85 USD -0.04 (-1.86%)
Updated Oct 20, 2020 10:42 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 572.81M
Revenue (ttm) 397,000
Net Income (ttm) -76.43M
Shares Out 310.47M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $1.85
Previous Close $1.88
Change ($) -0.04
Change (%) -1.86%
Day's Open 1.89
Day's Range 1.84 - 1.91
Day's Volume 374,144
52-Week Range 0.75 - 2.40

More Stats

Market Cap 572.81M
Enterprise Value 359.55M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 310.47M
Float 292.57M
EPS (basic) -0.37
EPS (diluted) -0.37
FCF / Share -0.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 44.18M
Short Ratio 12.59
Short % of Float 15.10%
Beta 1.69
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,442.85
PB Ratio 2.39
Revenue 397,000
Operating Income -79.64M
Net Income -76.43M
Free Cash Flow -61.67M
Net Cash 213.26M
Net Cash / Share 0.69
Gross Margin -9,774.06%
Operating Margin -20,059.45%
Profit Margin -19,251.60%
FCF Margin -15,533.25%
ROA -22.56%
ROE -37.49%
ROIC -50.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(116.80% upside)
Current: $1.85
Target: 4.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-56.85%0.09%-82.72%-83.06%3054.47%-10.13%-52.64%11.12%-31.57%-
Gross Profit0.461.071.076.1636.371.151.282.712.443.56
Operating Income-72.57-29.77-29.33-30.73-0.56-36.31-38.96-71.76-96.12-111
Net Income-68.55-27.02-27.92-29.540.05-35.67-38.38-68.88-96.85-111
Shares Outstanding19017715915915815412812712597.60
Earnings Per Share-0.36-0.15-0.18-0.19--0.23-0.30-0.54-0.78-1.14
Operating Cash Flow-43.83-21.01-20.56-18.37-24.209.35-36.68-55.15-62.39-44.29
Capital Expenditures-0.41-0.02--0.04-0.09-0.131.19-0.69-0.61-0.83
Free Cash Flow-44.24-21.03-20.56-18.41-24.299.22-35.49-55.84-63.00-45.13
Cash & Equivalents14016494.9511511415266.0296.33122187
Total Debt2.55---------
Net Cash / Debt13716494.9511511415266.0296.33122187
Book Value13517810412214213159.7685.65147193
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Geron Corporation
Country United States
Employees 45
CEO John A. Scarlett

Stock Information

Ticker Symbol GERN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GERN
IPO Date June 30, 1996


Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.